Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Allogene Therapeutics (ALLO) EBT Margin (2021 - 2024)

Allogene Therapeutics (ALLO) has disclosed EBT Margin for 4 consecutive years, with 291231.82% as the latest value for Q1 2024.

  • Quarterly EBT Margin rose 3221152.0% to 291231.82% in Q1 2024 from the year-ago period, while the trailing twelve-month figure was 1151031.82% through Dec 2024, down 82531603.0% year-over-year, with the annual reading at 1168850.0% for FY2024, 82436053.0% down from the prior year.
  • EBT Margin hit 291231.82% in Q1 2024 for Allogene Therapeutics, up from 375447.62% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 2.5% in Q4 2021 to a low of 375447.62% in Q4 2023.
  • Historically, EBT Margin has averaged 223087.67% across 4 years, with a median of 258140.91% in 2023.
  • Biggest five-year swings in EBT Margin: crashed -36014866bps in 2022 and later surged 4374428bps in 2023.
  • Year by year, EBT Margin stood at 2.5% in 2021, then crashed by -14392819bps to 360146.15% in 2022, then fell by -4bps to 375447.62% in 2023, then rose by 22bps to 291231.82% in 2024.
  • Business Quant data shows EBT Margin for ALLO at 291231.82% in Q1 2024, 375447.62% in Q4 2023, and 258140.91% in Q3 2023.